Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities (Tables)

v3.4.0.3
Accrued Expenses and Other Long-Term Liabilities (Tables)
3 Months Ended
Mar. 31, 2016
Payables and Accruals [Abstract]  
Components of Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities consisted of the following:
 
 
 
March 31,
 
December 31,
 
($ in thousands)
 
2016
 
2015
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
749
 
$
382
 
Salaries, bonuses and related benefits
 
 
762
 
 
2,492
 
Ovamed manufacturing rights - short term component
 
 
1,500
 
 
1,500
 
Research and development
 
 
746
 
 
810
 
Dr. Falk Pharma milestone
 
 
2,828
 
 
2,717
 
COH upfront fee for sponsored research for PepVax (see Note 6)
 
 
1,007
 
 
-
 
Accrued lease costs for abandoned properties
 
 
146
 
 
146
 
Other
 
 
521
 
 
523
 
Total accrued expenses
 
$
8,259
 
$
8,570
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Long-term accrued lease costs for abandoned properties
 
 
17
 
 
91
 
Deferred rent
 
 
2,399
 
 
493
 
Total other long-term liabilities
 
$
2,416
 
$
584